Literature DB >> 3798106

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire.   

Abstract

The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3798106     DOI: 10.1126/science.3798106

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  2000 in total

1.  The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.

Authors:  H Waterman; I Alroy; S Strano; R Seger; Y Yarden
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression.

Authors:  R R Tubbs; J Pettay; P Roche; M H Stoler; R Jenkins; J Myles; T Grogan
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

Review 3.  The role of fluorescence in situ hybridization technologies in molecular diagnostics and disease management.

Authors:  W King; J Proffitt; L Morrison; J Piper; D Lane; S Seelig
Journal:  Mol Diagn       Date:  2000-12

Review 4.  Protein kinases as therapeutic targets.

Authors:  R Sridhar; O Hanson-Painton; D R Cooper
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

Review 5.  ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

Authors:  R Pinkas-Kramarski; I Alroy; Y Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 6.  Clinically useful monoclonal antibodies in treatment.

Authors:  E Drewe; R J Powell
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

7.  Abstracts of the 8th International Pituitary Pathology Meeting. October 5-9, 2001. Greece.

Authors: 
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 8.  Methods of molecular analysis: assessing losses and gains in tumours.

Authors:  R Roylance
Journal:  Mol Pathol       Date:  2002-02

Review 9.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

Review 10.  Prognostic factors in breast cancer: current and new predictors of metastasis.

Authors:  D F Hayes; C Isaacs; V Stearns
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.